chr17-80112929-G-A
Variant summary
Our verdict is Pathogenic. The variant received 7 ACMG points: 7P and 0B. PP3PM3PM2_SupportingPS3_SupportingPP4_Moderate
This summary comes from the ClinGen Evidence Repository: The NM_000152.5:c.1942G>A (p.Gly648Ser) variant in GAA is a missense variant with a highest population minor allele frequency in gnomAD v2.1.1 of 0.00034 (10/29720 alleles) in the S. Asian population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). At least 18 patients with a diagnosis of Pompe disease have been reported with this variant including those with documented deficient GAA activity and/or symptoms consistent with infantile onset Pompe disease and/or on enzyme replacment therapy (PMIDs 9535769, 17573812, 26497565, 29422078, 30214072, 31510962) (PP4_Moderate). In a study of the Maroon population of French Guiana, 9 out of 15 probands with "enzymatically confirmed" infantile onset Pompe disease were compound heterozygous for c.1942G>A (p.Gly648Ser) and c.2560C>T (p.Arg854Ter), a variant which has been classified as pathogenic by the ClinGen LD VCEP. The two variants are assumed to be in trans based on the high carrier frequency of both variants in that population. The carrier frequency of c.1942G>A (p.Gly648Ser) was 1 in 47 (9/425 women tested) (PMID:29637184). Patients have also been reported who are compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP including c.2214G>A (p.Trp768Ter) (PMID:26575883) and c.-32-13T>G (2 patients, PMIDs: 17643989, 25455803, 27193587). In addition, at least 3 patients are homozygous for the variant (PMID:26497565, 29122469, 29889338, 30214072) (PM3_VeryStrong). Patients compound heterozygous for the variant and c.1076-22T>G (17643989, 25455803), c.2646+2T>A (PMID:29422078), and c.1099T>C (p.Trp367Arg) (PMID:31510962) have also been reported. However, the in trans data from these patients will be used in the assessment of the second variant and was not included here in order to avoid circular logic. When expressed in SV40_immortalized GAA deficient fibroblasts, the enzyme activity was "negligible" (PMID:9535769), and when expressed in COS cells, the variant resulted in <2% wild type GAA activity (PMID:19862843) (PS3_Supporting). The score for the REVEL meta-predictor, 0.98, also supports that the variant has a deleterious impact on GAA function (PP3). Another amino acid substitution at the same position has been reported in at least one individual with Pompe disease c.1943G>A (p.Gly648Asp) (PMIDs 22644586, 23146291, 23843830) (note that this data will be used in the classification of p.Gly648Asp and was not used here in order to avoid a circular argument). There is a ClinVar entry for this variant (Variation ID: 188902). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria met, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PM3_VeryStrong, PP4_Moderate, PP3, PS3_Supporting, PM2_Supporting.(Classification approved by the ClinGen Lysosomal Diseases VCEP, July 3, 2023) LINK:https://erepo.genome.network/evrepo/ui/classification/CA274102/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 missense
Scores
Clinical Significance
Conservation
Publications
- glycogen storage disease IIInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), G2P, Laboratory for Molecular Medicine
- glycogen storage disease due to acid maltase deficiency, infantile onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- glycogen storage disease due to acid maltase deficiency, late-onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 7 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000152.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAA | MANE Select | c.1942G>A | p.Gly648Ser | missense | Exon 14 of 20 | NP_000143.2 | P10253 | ||
| GAA | c.1942G>A | p.Gly648Ser | missense | Exon 15 of 21 | NP_001073271.1 | P10253 | |||
| GAA | c.1942G>A | p.Gly648Ser | missense | Exon 14 of 20 | NP_001073272.1 | P10253 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAA | TSL:1 MANE Select | c.1942G>A | p.Gly648Ser | missense | Exon 14 of 20 | ENSP00000305692.3 | P10253 | ||
| GAA | TSL:1 | c.1942G>A | p.Gly648Ser | missense | Exon 15 of 21 | ENSP00000374665.3 | P10253 | ||
| GAA | c.1957G>A | p.Gly653Ser | missense | Exon 14 of 20 | ENSP00000603465.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152174Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000536 AC: 13AN: 242472 AF XY: 0.0000758 show subpopulations
GnomAD4 exome AF: 0.0000199 AC: 29AN: 1458310Hom.: 0 Cov.: 33 AF XY: 0.0000290 AC XY: 21AN XY: 725154 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152292Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74464 show subpopulations
Age Distribution
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at